Low-Density Lipoprotein Cholesterol and Metabolic Syndrome in an Iranian High-Risk Population Publisher Pubmed



Janghorbani M^{1, 2} ; Amini M¹ Show Affiliations
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews Published:2015

Abstract

Aim Currently, one study support the hypothesis that low-density lipoprotein cholesterol (LDLC) is associated with metabolic syndrome (MetS) independent of pre-existing components of MetS. In this study we further evaluated the ability of the LDLC to predict prevalence and incidence of MetS in an Iranian high-risk population. Materials and methods We analyzed baseline (n = 3396) and 7-year follow-up data (n = 865) in first-degree relatives (FDR) of consecutive patients with type 2 diabetes 30-70 years old. We used logistic regression to estimate the odds ratio (OR) for prevalent MetS, and Cox proportional hazard models to estimate hazard ratio (HR) for incident MetS across quartiles of LDLC and plotted a receiver operating characteristic (ROC) curve to assess discrimination. Results The highest quartile of LDLC compared with the lowest quartile was associated with MetS in both the prevalent (OR 1.39, 95% CI 1.13, 1.70) and incident in unadjusted models (HR 1.24, 95% CI 1.03, 1.49). Adjusted for age, gender and pre-existing components of MetS attenuated association for both prevalent (OR 1.15, 95% CI 0.83, 1.59) and incident MetS (HR 1.13, 95% CI 0.93, 1.38). The area under the ROC was 52.8% (95% CI 50.7, 55.0) for prevalent and 51.8% (95% CI 47.2, 56.3) for incident MetS. Conclusion The results of this study highlight that LDLC level is not a robust predictor of MetS, independent of age, gender or the pre-existing components of MetS, in high-risk individuals in Iran. © 2015 Diabetes India. Published by Elsevier Ltd. All rights reserved.